Breaking News

The potential loophole in Trump’s 'most-favored nations' policy

March 24, 2026
Pharmalot Columnist, Senior Writer
Patrick Soon-Shiong is the founder and executive chairman of ImmunityBio.
Kevork Djansezian/Getty Images

STAT+ | FDA slams Soon-Shiong and ImmunityBio for making 'false and misleading' claims about a drug

The FDA sent a warning letter in which it maintained 'material facts' and risks associated with the cancer drug were omitted.

By Ed Silverman


STAT+ | FTC strikes proposed deal with CVS over charges its PBM manipulated insulin prices, impeded access

CVS says the proposed agreement is subject to review and approval by the FTC chair, and that final terms are still pending.

By Ed Silverman


STAT+ | Drug company penalties for paying kickbacks to doctors failed to dent bottom lines, analysis finds

JAMA Network Open study finds kickback penalties dwarfed by profits: $10.25 billion in penalties versus U.S. revenue of $458.6 billion on drug sales.

By Ed Silverman



Top federal health official Chris Klomp speaks during an announcement on prescription drugs in the Oval Office in 2025.
BRENDAN SMIALOWSKI/AFP via Getty Images

STAT+ | The potential loophole in Trump's plan to get other countries to pay more for drugs

Trump health official is telling Republicans MFN drug pricing isn't about lowering U.S. costs. It's about forcing the world to pay more.

By John Wilkerson


More around STAT
Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

Enjoying Pharmalot? Tell us about your experience
Continue reading the latest health & science news with the STAT app
Download on the App Store or get it on Google Play
STAT
STAT, 1 Exchange Place, Boston, MA
©2026, All Rights Reserved.

No comments